Tifcemalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase III for Small-Cell Lung Cancer. According to GlobalData, Phase III drugs for Small-Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tifcemalimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Tifcemalimab overview

Tifcemalimab is under development for the treatment of recurrent/refractory malignant lymphoma, hodgkin lymphoma (b-cell hodgkin lymphoma), non-hodgkin lymphoma including follicular lymphoma, metastatic pancreatic cancer, solid tumors including non-small cell lung cancer, melanoma, Hodgkin lymphoma, urothelial carcinoma, renal cell carcinoma, recurrent or metastatic head and neck squamous cell carcinoma, squamous non-small cell lung carcinoma, non-small cell lung carcinoma, small cell lung cancer and nasopharyngeal carcinoma. It is a monoclonal antibody which is administered through intravenous route. It acts by targeting BTLA (B- and T-lymphocyte attenuator).

Shanghai Junshi Biosciences overview

Shanghai Junshi Biosciences (Junshi Biotech) is a biopharmaceutical company that discovers, develops and commercialization of novel therapies. The company offers products for various diseases including tumor immunotherapy, autoimmune system diseases, chronic metabolic diseases, neurological diseases, and infectious diseases. Junshi Biotech products include toripalimab injection, adalimumab, Deuterated and etesevirumab. Its other pipelines include JS211, JS209, JS208, JS121, JS115, JS114, JS019 and others. It works in partnership with Coherus and Conlida for the development and commercialization of its products. The company operates its research and development centers in the US and China. Junshi Biotech is headquartered in Shanghai, China.

For a complete picture of Tifcemalimab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.